the FDA likely isn't too keen on monotherapy, jus

Quote:

---

the FDA likely isn't too keen on monotherapy, just because HIV has been a combo disease by nature forever.

---

Why the FDA insisted on the combo trial was the potential for viral rebound or having to stop use of the drug due to side effects. The FDA based that on the results from Maraviroc which was approved only in combo.

Quote:

---

functional cure is here its at. that will take quite a long time. a strong preclinical result being published perhaps in 2024 or 2025 would a big help for the share price.

---

That will depend on how far along Dr. Sacha is on his research. He comes out with a paper with numerous macaques it will show his single macaque wasn't an aberration then maybe people will sit up and take notice.

There's also the preclinical Cytodyn wants to do with NASH. They should be starting that ASAP and get ahead of the game. If they do a paper could be released in the first quarter of 2024.